Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

PURPOSE: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies for myelodysplastic syndromes and acute myelogenous leukemias. Several attempts to improve outcomes by combining HMAs with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavras, Phaedon D., Shastri, Aditi, Goldfinger, Mendel, Verma, Amit K., Saunthararajah, Yogen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678301/
https://www.ncbi.nlm.nih.gov/pubmed/34551907
http://dx.doi.org/10.1158/1078-0432.CCR-21-2139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678301/
https://www.ncbi.nlm.nih.gov/pubmed/34551907
http://dx.doi.org/10.1158/1078-0432.CCR-21-2139

Ejemplares similares